Cardiac molecular pathways influenced by doxorubicin treatment in mice

Ben F. Bulten, Martina Sollini, Roberto Boni, Katrin Massri, Lioe-Fee de Geus-Oei, Hanneke W. M. van Laarhoven, Riemer H. J. A. Slart, Paola A. Erba

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Doxorubicin (DOX) is a potent chemotherapeutic with distinct cardiotoxic properties. Understanding the underlying cardiotoxic mechanisms on a molecular level would enable the early detection of cardiotoxicity and implementation of prophylactic treatment. Our goal was to map the patterns of different radiopharmaceuticals as surrogate markers of specific metabolic pathways induced by chemotherapy. Therefore, cardiac distribution of 99m Tc-sestamibi, 99m Tc-Annexin V, 99m Tc-glucaric acid and [ 18 F]FDG and cardiac expression of Bcl-2, caspase-3 and -8, TUNEL, HIF-1α, and p53 were assessed in response to DOX exposure in mice. A total of 80 mice (64 treated, 16 controls) were evaluated. All radiopharmaceuticals showed significantly increased uptake compared to controls, with peak cardiac uptake after one ( 99m Tc-Annexin V), two ( 99m Tc-sestamibi), three ([ 18 F]FDG), or four ( 99m Tc-glucaric acid) cycles of DOX. Strong correlations (p < 0.01) were observed between 99m Tc-Annexin V, caspase 3 and 8, and TUNEL, and between [ 18 F]FDG and HIF-1α. This suggests that the cardiac DOX response starts with apoptosis at low exposure levels, as indicated by 99m Tc-Annexin V and histological apoptosis markers. Late process membrane disintegration can possibly be detected by 99m Tc-sestamibi and 99m Tc-glucaric acid. [ 18 F]FDG signifies an early adaptive response to DOX, which can be further exploited clinically in the near future.
Original languageEnglish
Article number2514
JournalScientific Reports
Volume9
Issue number1
DOIs
Publication statusPublished - 2019

Cite this

Bulten, B. F., Sollini, M., Boni, R., Massri, K., de Geus-Oei, L-F., van Laarhoven, H. W. M., ... Erba, P. A. (2019). Cardiac molecular pathways influenced by doxorubicin treatment in mice. Scientific Reports, 9(1), [2514]. https://doi.org/10.1038/s41598-019-38986-w
Bulten, Ben F. ; Sollini, Martina ; Boni, Roberto ; Massri, Katrin ; de Geus-Oei, Lioe-Fee ; van Laarhoven, Hanneke W. M. ; Slart, Riemer H. J. A. ; Erba, Paola A. / Cardiac molecular pathways influenced by doxorubicin treatment in mice. In: Scientific Reports. 2019 ; Vol. 9, No. 1.
@article{84ff740df4464c148cce41ad5700fe33,
title = "Cardiac molecular pathways influenced by doxorubicin treatment in mice",
abstract = "Doxorubicin (DOX) is a potent chemotherapeutic with distinct cardiotoxic properties. Understanding the underlying cardiotoxic mechanisms on a molecular level would enable the early detection of cardiotoxicity and implementation of prophylactic treatment. Our goal was to map the patterns of different radiopharmaceuticals as surrogate markers of specific metabolic pathways induced by chemotherapy. Therefore, cardiac distribution of 99m Tc-sestamibi, 99m Tc-Annexin V, 99m Tc-glucaric acid and [ 18 F]FDG and cardiac expression of Bcl-2, caspase-3 and -8, TUNEL, HIF-1α, and p53 were assessed in response to DOX exposure in mice. A total of 80 mice (64 treated, 16 controls) were evaluated. All radiopharmaceuticals showed significantly increased uptake compared to controls, with peak cardiac uptake after one ( 99m Tc-Annexin V), two ( 99m Tc-sestamibi), three ([ 18 F]FDG), or four ( 99m Tc-glucaric acid) cycles of DOX. Strong correlations (p < 0.01) were observed between 99m Tc-Annexin V, caspase 3 and 8, and TUNEL, and between [ 18 F]FDG and HIF-1α. This suggests that the cardiac DOX response starts with apoptosis at low exposure levels, as indicated by 99m Tc-Annexin V and histological apoptosis markers. Late process membrane disintegration can possibly be detected by 99m Tc-sestamibi and 99m Tc-glucaric acid. [ 18 F]FDG signifies an early adaptive response to DOX, which can be further exploited clinically in the near future.",
author = "Bulten, {Ben F.} and Martina Sollini and Roberto Boni and Katrin Massri and {de Geus-Oei}, Lioe-Fee and {van Laarhoven}, {Hanneke W. M.} and Slart, {Riemer H. J. A.} and Erba, {Paola A.}",
year = "2019",
doi = "10.1038/s41598-019-38986-w",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Bulten, BF, Sollini, M, Boni, R, Massri, K, de Geus-Oei, L-F, van Laarhoven, HWM, Slart, RHJA & Erba, PA 2019, 'Cardiac molecular pathways influenced by doxorubicin treatment in mice' Scientific Reports, vol. 9, no. 1, 2514. https://doi.org/10.1038/s41598-019-38986-w

Cardiac molecular pathways influenced by doxorubicin treatment in mice. / Bulten, Ben F.; Sollini, Martina; Boni, Roberto; Massri, Katrin; de Geus-Oei, Lioe-Fee; van Laarhoven, Hanneke W. M.; Slart, Riemer H. J. A.; Erba, Paola A.

In: Scientific Reports, Vol. 9, No. 1, 2514, 2019.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Cardiac molecular pathways influenced by doxorubicin treatment in mice

AU - Bulten, Ben F.

AU - Sollini, Martina

AU - Boni, Roberto

AU - Massri, Katrin

AU - de Geus-Oei, Lioe-Fee

AU - van Laarhoven, Hanneke W. M.

AU - Slart, Riemer H. J. A.

AU - Erba, Paola A.

PY - 2019

Y1 - 2019

N2 - Doxorubicin (DOX) is a potent chemotherapeutic with distinct cardiotoxic properties. Understanding the underlying cardiotoxic mechanisms on a molecular level would enable the early detection of cardiotoxicity and implementation of prophylactic treatment. Our goal was to map the patterns of different radiopharmaceuticals as surrogate markers of specific metabolic pathways induced by chemotherapy. Therefore, cardiac distribution of 99m Tc-sestamibi, 99m Tc-Annexin V, 99m Tc-glucaric acid and [ 18 F]FDG and cardiac expression of Bcl-2, caspase-3 and -8, TUNEL, HIF-1α, and p53 were assessed in response to DOX exposure in mice. A total of 80 mice (64 treated, 16 controls) were evaluated. All radiopharmaceuticals showed significantly increased uptake compared to controls, with peak cardiac uptake after one ( 99m Tc-Annexin V), two ( 99m Tc-sestamibi), three ([ 18 F]FDG), or four ( 99m Tc-glucaric acid) cycles of DOX. Strong correlations (p < 0.01) were observed between 99m Tc-Annexin V, caspase 3 and 8, and TUNEL, and between [ 18 F]FDG and HIF-1α. This suggests that the cardiac DOX response starts with apoptosis at low exposure levels, as indicated by 99m Tc-Annexin V and histological apoptosis markers. Late process membrane disintegration can possibly be detected by 99m Tc-sestamibi and 99m Tc-glucaric acid. [ 18 F]FDG signifies an early adaptive response to DOX, which can be further exploited clinically in the near future.

AB - Doxorubicin (DOX) is a potent chemotherapeutic with distinct cardiotoxic properties. Understanding the underlying cardiotoxic mechanisms on a molecular level would enable the early detection of cardiotoxicity and implementation of prophylactic treatment. Our goal was to map the patterns of different radiopharmaceuticals as surrogate markers of specific metabolic pathways induced by chemotherapy. Therefore, cardiac distribution of 99m Tc-sestamibi, 99m Tc-Annexin V, 99m Tc-glucaric acid and [ 18 F]FDG and cardiac expression of Bcl-2, caspase-3 and -8, TUNEL, HIF-1α, and p53 were assessed in response to DOX exposure in mice. A total of 80 mice (64 treated, 16 controls) were evaluated. All radiopharmaceuticals showed significantly increased uptake compared to controls, with peak cardiac uptake after one ( 99m Tc-Annexin V), two ( 99m Tc-sestamibi), three ([ 18 F]FDG), or four ( 99m Tc-glucaric acid) cycles of DOX. Strong correlations (p < 0.01) were observed between 99m Tc-Annexin V, caspase 3 and 8, and TUNEL, and between [ 18 F]FDG and HIF-1α. This suggests that the cardiac DOX response starts with apoptosis at low exposure levels, as indicated by 99m Tc-Annexin V and histological apoptosis markers. Late process membrane disintegration can possibly be detected by 99m Tc-sestamibi and 99m Tc-glucaric acid. [ 18 F]FDG signifies an early adaptive response to DOX, which can be further exploited clinically in the near future.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85061985276&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30792528

U2 - 10.1038/s41598-019-38986-w

DO - 10.1038/s41598-019-38986-w

M3 - Article

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 2514

ER -